scholarly journals A comparative study of effect of epidermal growth factor on chronic leg ulcers with anti-septic dressing

2021 ◽  
Author(s):  
Mallikarjuna Reddy M. ◽  
Vijayabhaskarreddy Sirigireddy
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Chronic Wounds ◽  
Substantial Reduction ◽  
Test Group ◽  
Control Group ◽  
Medical College ◽  
Group A ◽  
Epidermal Growth ◽  
Healing Wounds

Background: Chronic wounds, particularly non-healing wounds, are one of the most prevalent surgical disorders that a surgeon may see. The characteristic of a chronic wound is that it does not heal despite daily dressings and costly local treatments. Aims of the study to investigate the healing effects of recombinant human epidermal growth factor (hEGF) on non-healing ulcers and to assess the effectiveness, acceptability, and safety of a new epidermal growth factor (EGF) wound dressing.Methods: On 60 patients with chronic non-healing ulcers, a randomized, prospective, and comparative research was conducted in the department of general surgery, SVS medical college and hospital, Mahbubnagar. These 60 patients were separated into two groups, each with fifteen patients. The EGF was applied to group A, whereas normal saline was given to group B.Results: The 60 patients who agreed to participate in the trial were separated into two groups (30 each) that were equal and comparable. Patients who received topical EGF 0.01% gel dressings were assigned to the trial, whereas those who received standard antiseptic wound dressing were assigned to the control group. Six of the fifteen patients in the test group were men, whereas eleven were males and four were females in the control group. When the two groups were compared, the test group had a substantial reduction in ulcer area compared to the control group (p<0.001)Conclusions: EGF is a superior alternative for treating chronic non-healing ulcers because of its cost effectiveness, availability, reduced hospital stay, and simplicity of administration.

scholarly journals Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252646
Author(s):  
Margot Geens ◽  
Sofie Stappers ◽  
Heleen Konings ◽  
Benedicte Y. De Winter ◽  
Pol Specenier ◽  
...  
Keyword(s):  
Lymph Node ◽  
Growth Factor ◽  
Lymph Node Metastasis ◽  
Epidermal Growth Factor ◽  
Healthy Volunteers ◽  
Control Group ◽  
Node Metastasis ◽  
Oncological Patients ◽  
Platinum Based Chemotherapy ◽  
Epidermal Growth

In this study, we investigated serum epidermal growth factor (EGF) in an oncological population of head- and neck and pulmonary neoplasms and whether serum EGF could serve as a prognostic marker of survival and as a predictive marker for treatment response to platinum-based chemotherapy. A total of 59 oncological patients and a control group of age- and sex-matched healthy volunteers were included in this study. Pre-treatment serum EGF from both groups was determined. Patient’s and tumour characteristics and mortality were recorded during a 5-year follow up period. Baseline serum EGF significantly differed between the oncological patients and the healthy volunteers (p<0.001). Serum EGF was associated with lymph node metastasis (p = 0.004) but not with sex (p = 0.753), age (p = 1.00), TNM stage (p = 0.191) or tumour size (p = 0.077). Neither serum EGF (p = 0.81) nor age (p = 0.55) showed an effect on the patient’s survival. Tumour location was significantly associated with overall 5-year survival (p = 0.003). The predictive capacity of serum EGF of response to chemotherapy was limited (AUC = 0.606), a sensitivity of 80% and a specificity of 56% was observed resulting in a likelihood ratio of a positive and negative test equal to 1.81 and 0.36, respectively. In conclusion, serum EGF levels are 5.5 times higher in an oncological population compared to a control group. Within the oncological population, low serum EGF values are associated with the presence of lymph node metastasis. Further investigation is necessary to determine if the serum EGF levels could serve as a diagnostic biomarker.

The effect of epidermal growth factor on liver lipid peroxidation and glutathione levels in lobectomized rats

1992 ◽  
Vol 70 (3-4) ◽  
pp. 259-262 ◽  
Author(s):  
Nahide Gokcora ◽  
Sadi Gundogdu ◽  
Aysel Aricioglu ◽  
Deniz Erbas ◽  
Osman Durmus ◽  
...  
Keyword(s):  
Lipid Peroxidation ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Liver Lipid ◽  
Lipid Peroxide ◽  
Submaxillary Gland ◽  
Control Group ◽  
Key Factor ◽  
Male Wistar Rats ◽  
Epidermal Growth

Epidermal growth factor (EGF) is a growth-promoting polypeptide which is found in highest levels in male mice in the submaxillary gland. It may also be a key factor in regeneration of the liver. We performed experiments with 18 male Wistar rats, divided into three groups. Hepatic left lobectomy (%30) was performed on the first group of rats. This group received an intraperitoneal injection of EGF for 7 days. The second group was the control group into which normal saline was injected for 7 days. The third group was sham-operated. On days 5 and 7 tomographic studies of liver were performed. On day 7 EGF levels, lipid peroxidation, and glutathione in liver were measured in all of the rats. While serum EGF levels did not show any significant change, the levels of lipid peroxide were decreased and glutathione was increased. Tomographic measurements indicated that administration of EGF increased the amount of regeneration.Key words: epidermal growth factor, liver lobectomy, lipid peroxide, glutathione, radioimmunoassay.

PSX-B-13 Effect of epidermal growth factor and prolactin on the quality of bovine oocytes aging in vitro

2021 ◽  
Vol 99 (Supplement_3) ◽  
pp. 327-327
Author(s):  
Ekaterina Shedova ◽  
Galina Singina ◽  
Irina Y Lebedeva ◽  
Aleksandr Lopukhov
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Control Group ◽  
Tunel Staining ◽  
Apoptosis Resistance ◽  
Prolonged Culture ◽  
Epidermal Growth ◽  
Bovine Oocytes

Abstract The evaluation of factors responsible for the protection of the oocytes attained the metaphase-II stage from aging is importance for successful in vitro embryo reproduction. The aim of the present research was to study dose-dependent effects of epidermal growth factor (EGF) and prolactin (PRL) on the quality of bovine oocytes after their aging in vitro. Bovine cumulus-enclosed oocytes (CEOs) were matured in vitro for 20 h in TCM 199 containing 0.2 mM sodium pyruvate, 10% fetal calf serum (FCS), 10 μg/ml FSH and LH. At the end of in vitro maturation, oocytes were transferred to TCM 199 supplemented with 10% FCS (aging medium) and cultured for additional 24 h in the absence (Control) and in presence of EGF (10 and 50 ng/ml) and PRL (20 and 50 ng/ml). After prolonged culture oocytes were used for apoptosis detection (TUNEL staining, n=251) and the state of chromosomes evaluation (Tarkowski’s cytogenetic method, n=359). The data from 3–4 replicates were analyzed by ANOVA. At the end of prolonged culture (24 h) the rate of apoptotic oocytes in the Control group was 47.4±8.5%. EGF at concentration of 10 ng/ml and PRL at both doses decreased this rate to 15.0–22.1% (p &lt; 0.05). Furthermore, PRL (not EGF) reduced the frequency of abnormal chromosome modifications (decondensation, adherence, clumping) at concentrations of 20–50 ng/ml from 58.7±2.1% (Control) to 41.2±1.9 and 45.6±2.7% respectively (p &lt; 0.01). Thus, EGF and PRL is able to maintain the apoptosis resistance of bovine oocytes during their prolonged in vitro culture as well as PRL have the decelerating effect on abnormal modifications of M-II chromosomes. The research was supported by RFBR (17-29-08035) and the Ministry of Science and Higher Education of Russia.

scholarly journals Effects of dietary supplementation with epidermal growth factor-expressing Saccharomyces cerevisiae on duodenal development in weaned piglets

2016 ◽  
Vol 115 (9) ◽  
pp. 1509-1520 ◽  
Author(s):  
Shujin Wang ◽  
Chunhua Guo ◽  
Lin Zhou ◽  
Zhendong Zhong ◽  
Wuzheng Zhu ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Digestive Enzymes ◽  
Egf Receptor ◽  
Average Daily Gain ◽  
Dietary Supplementation ◽  
Control Group ◽  
Weaned Piglets ◽  
Epidermal Growth

AbstractThe aim of the present study was to assess the effects of dietary supplementation with epidermal growth factor (EGF)-expressing Saccharomyces cerevisiae on duodenal development in weaned piglets. In total, forty piglets weaned at 21–26 d of age were assigned to one of the five groups that were provided basic diet (control group) or diet supplemented with S. cerevisiae expressing either empty-vector (INVSc1(EV) group), tagged EGF (T-EGF) (INVSc1-TE(−) group), extracellular EGF (EE-EGF) (INVSc1-EE(+) group) or intracellular EGF (IE-EGF) (INVSc1-IE(+) group). All treatments were delivered as 60·00 μg/kg body weight EGF/d. On 0, 7, 14 and 21 d, eight piglets per treatment were sacrificed to analyse the morphology, activities and mRNA expressions of digestive enzymes, as well as Ig levels (IgA, IgM, IgG) in duodenal mucosa. The results showed significant improvement on 7, 14 and 21 d, with respect to average daily gain (P<0·05), mucosa morphology (villus height and crypt depth) (P<0·05), Ig levels (P<0·01), activities and mRNA expressions of digestive enzymes (creatine kinase, alkaline phosphatase, lactate dehydrogenase and sucrase) (P<0·05) and the mRNA expression of EGF-receptor (P<0·01) in NVSc1-TE(−), INVSc1-EE(+) and INVSc1-IE(+) groups compared with control and INVSc1(EV) groups. In addition, a trend was observed in which the INVSc1-IE(+) group showed an improvement in Ig levels (0·05<P<0·10), mRNA expressions of digestive enzymes and EGF-receptor (P<0·05) compared with NVSc1-TE(−) and INVSc1-EE(+) groups. These results indicate that supplementing recombinant EGF-expressing S. cerevisiae to the diet of weaned piglets enhanced duodenal development. Moreover, biological activity (Ig levels, mRNA expressions of digestive enzymes and EGF-receptor) of IE-EGF was better than either EE-EGF or T-EGF.

scholarly journals Therapeutic Effect of Epidermal Growth Factor Combined With Nano Silver Dressing on Diabetic Foot Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Kaihua Zhang ◽  
Yiran Li ◽  
Jiarui He ◽  
Jiasheng Xu ◽  
Yanhua Wan ◽  
...  
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Factor Group ◽  
Saline Control ◽  
Control Group ◽  
Nano Silver ◽  
Significant Difference ◽  
Epidermal Growth

Objective: To investigate the clinical efficacy of epidermal growth factor combined with nano silver dressing in the treatment of diabetic foot wounds.Methods: A total of 160 patients with diabetic foot ulcers admitted to the Second Affiliated Hospital of Nanchang University from 2015-06 to 2018-06 were selected to participate in the experiment. A randomized table method was used to randomly divide 160 patients into 4 groups: 40 in the epidermal growth factor group, 40 in the nano-silver dressing group, 40 in the combined group, and 40 in the saline control group (normal saline). The healing stage of the wound surface and the growth degree of granulation tissue were graded. Each group was given a dressing change every other day, and the time required for wound repairing to each healing stage was observed. After 2 and 4 weeks of treatment, the wound exudate was collected for bacterial culture.Results: There was no significant difference in the time between the four groups of patients reaching the effective phase of treatment (level 1). Compared with the control group, the epidermal growth factor group and the combined group achieved a shorter time for wound repairing to healing stages 2 and 3, and the difference was significant (p &lt; 0.05). The combined group had a shorter wound repairing time than the epidermal growth factor group (p &lt; 0.05). Compared with the control group, the positive rate of bacteria in the combined group and the silver nanoparticles group was significantly lower after 2 and 4 weeks of treatment.Conclusion: There is no significant difference in wound healing between the four groups during the clinically effective period. After this period, the combined use of recombinant epidermis Growth factors and nano-silver dressings have a significant effect on promoting wound healing and can effectively prevent infection.

scholarly journals Expression of Gallus Epidermal Growth Factor (gEGF) with Food-Grade Lactococcus lactis Expression System and Its Biological Effects on Broiler Chickens

Biomolecules ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 103
Author(s):  
Yu Zhou ◽  
Pinpin Chen ◽  
Shuai Shi ◽  
Xiaowen Li ◽  
Deshi Shi ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Performance ◽  
Lactococcus Lactis ◽  
Broiler Chickens ◽  
Biological Effects ◽  
Expression System ◽  
Control Group ◽  
Fermentation Product ◽  
Epidermal Growth

As a multifunctional polypeptide, epidermal growth factor (EGF) increases growth performance or enhances resistance to diseases in commercial broilers under adverse conditions. In this study, a recombinant Lactococcus lactis was established to produce the secretory form of bioactive gEGF. The results of in vitro testing showed that gEGF promoted the proliferation of chicken embryo fibroblast cells. A total of 63 5-day-old broiler chickens were evenly divided into three groups and treated with either M17 medium (the control group), supernatant of LL-pNZ8149 fermentation product (the P-LL group), or supernatant of LL-pNZ8149-gEGF fermentation product (the gEGF group). In two weeks, many measurements of growth, immunity and the intestines were significantly higher in the gEGF group than those in the control and the P-LL groups. Our study showed that the bioactive gEGF could be expressed with Lactococcus lactis expression system with the potential to enhance growth performance, immune function, and intestinal development in broiler chickens.

EGFRvIII peptide nanocapsules and bevacizumab nanocapsules: a nose-to-brain multitarget approach against glioblastoma

Nanomedicine ◽  
2021 ◽  
Author(s):  
Aline de Cristo Soares Alves ◽  
Vladimir Lavayen ◽  
Amanda de Fraga Dias ◽  
Franciele Aline Bruinsmann ◽  
Juliete Nathali Scholl ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
T Lymphocytes ◽  
Epidermal Growth Factor ◽  
Tumor Size ◽  
Growth Factor Receptor ◽  
Molecular Targets ◽  
Control Group ◽  
Brain Delivery ◽  
Epidermal Growth

Aim: To evaluate the antitumor efficacy of bevacizumab-functionalized nanocapsules in a rat glioblastoma model after the pretreatment with nanocapsules functionalized with a peptide-specific to the epidermal growth factor receptor variant III. Materials & methods: Nanocapsules were prepared, physicochemical characterized and intranasally administered to rats. Parameters such as tumor size, histopathological characteristics and infiltration of CD8+ T lymphocytes were evaluated. Results: The strategy of treatment resulted in a reduction of 87% in the tumor size compared with the control group and a higher infiltration of CD8+ T lymphocytes in tumoral tissue. Conclusion: The block of two different molecular targets using nose-to-brain delivery represents a new and promising approach against glioblastoma.

Efficacy of Growth Factor in Promoting Early Osseointegration

2014 ◽  
Vol 40 (5) ◽  
pp. 543-548 ◽  
Author(s):  
Khalid Al-Hezaimi ◽  
Myron Nevins ◽  
Soo-Woo Kim ◽  
Ardavan Fateh ◽  
David M. Kim
Keyword(s):  
Growth Factor ◽  
Close Contact ◽  
Fibrous Tissue ◽  
Test Group ◽  
Preclinical Study ◽  
Histological Evaluation ◽  
Control Group ◽  
Implant Surface ◽  
Coated Implant ◽  
Group A

A preclinical study was conducted to evaluate the feasibility of 2 different topical formulations of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) to promote early osseointegration and enhanced bone-to-implant contact (BIC) for dental implants placed in an edentulous ridge. Six female beagle dogs were divided into 3 groups. The control group included 4 implants with no coating; test group A included 10 implants with commercially available rhPDGF-BB formulation coating; and second test group B included 10 implants with prototype viscous rhPDGF-BB coating. Three dogs were sacrificed at 3 weeks (12 implants) and the remaining 3 dogs at 6 weeks after implant placement (12 implants). The specimens were retrieved for histological evaluation, and revealed an uneventful healing of all implants without any sign of an inflammatory response at the different time intervals. Furthermore, the bone was in very close contact with the implants' surfaces with no evidence of intervening fibrous tissue layers. At 3 weeks, new bone formation between most implant threads on rhPDGF-BB coated implants was evident, whereas in the control group only a thin and sparse amount of new bone was noted. At 6 weeks, the commercially available rhPDGF-BB formulation coated implant group (Group A) showed more trabecular bone and higher BIC compared to the other 2 groups. Histologically, the results in this study showed that use of conventionally available rhPDGF-BB formulation as the implant surface treatment may accelerate the process of osseointegration and enhance BIC.

Sign in / Sign up

Export Citation Format

Share Document